Literature DB >> 4162448

Structural studies of human gamma-G-myeloma proteins of different antigenic subgroups and genetic specificities.

B Frangione, E C Franklin, H H Fudenberg, M E Koshland.   

Abstract

1. Peptide maps of Fc fragments or heavy chains of 36 G myeloma proteins and two "heavy chain disease" proteins belonging to the four gamma-chain subgroups revealed very striking similarities between them. However differences in a few peptides were noted. This was most pronounced for the Ge(gamma(2)d) subgroup which lacked three peptides characteristic of the other three subgroups. While Fc fragments from different proteins belonging to the same subgroup appeared very similar, minor differences in addition to those based on currently recognized Gm factors were occasionally noted. 2. Fc fragments from Gm(a+) We(gamma(2)b) proteins had a peptide previously shown to be characteristic of normal Gm(a+) gammaG-globulins. Fc fragments from Gm(a-) molecules belonging to the We(gamma(2)b), Vi(gamma(2)c), or Ne(gamma(2)a) subgroups, whether Gm(b+), Gm(f+), or Gm(-), had the peptide previously identified in Gm(b+f+) normal gammaG-globulin. This "non-a" peptide was absent in peptide maps from Gm(-) molecules of the Ge(gamma(2)d) subgroup which contained instead another peptide with the same electrophoretic mobility but migrating slightly further on chromatography. 3. Both the "a" and "non-a" peptides were pentapeptides having three amino acids in common, and differing in the other two. The "a" peptide contained one residue of lysine, aspartic acid, threonine, leucine, and glutamic acid. The "non-a" peptides prepared from Gm(b+), Gm(f+), and Gm(-) proteins were identical and contained one residue of lysine, threonine, and methionine sulfone, and two residues of glutamic acid. 4. Several possible mechanisms for the origin of these differences, and their possible role in serologic specificity are discussed.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 4162448      PMCID: PMC2138254          DOI: 10.1084/jem.124.4.715

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

1.  HETEROGENEITY OF H CHAINS OF MYELOMA PROTEINS: SUSCEPTIBILITY TO PAPAIN AND TRYPSIN.

Authors:  M D POULIK; J SHUSTER
Journal:  Nature       Date:  1964-11-07       Impact factor: 49.962

2.  Reduction of gamma-globulins.

Authors:  J B FLEISCHMAN; R H PAIN; R R PORTER
Journal:  Arch Biochem Biophys       Date:  1962-09       Impact factor: 4.013

3.  Peptide separation by two-dimensional chromatography and electrophoresis.

Authors:  A M KATZ; W J DREYER; C B ANFINSEN
Journal:  J Biol Chem       Date:  1959-11       Impact factor: 5.157

4.  Agglutination of erythrocytes coated with incomplete anti-Rh by certain rheumatoid arthritic sera and some other sera; the existence of human serum groups.

Authors:  R GRUBB
Journal:  Acta Pathol Microbiol Scand       Date:  1956

5.  Hereditary serological human serum groups.

Authors:  R GRUBB; A B LAURELL
Journal:  Acta Pathol Microbiol Scand       Date:  1956

6.  Zone electrophoresis.

Authors:  H G KUNKEL
Journal:  Methods Biochem Anal       Date:  1954

7.  The molecular basis of antibody formation: a paradox.

Authors:  W J Dreyer; J C Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  1965-09       Impact factor: 11.205

8.  SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS.

Authors:  W D TERRY; J L FAHEY
Journal:  Science       Date:  1964-10-16       Impact factor: 47.728

9.  Genetic characters of human gamma-globulins in myeloma proteins.

Authors:  M HARBOE; C K OSTERLAND; M MANNIK; H G KUNKEL
Journal:  J Exp Med       Date:  1962-11-01       Impact factor: 14.307

10.  Properties of guinea pig 7S antibodies. I. Electrophoretic separation of two types of guinea pig 7S antibodies.

Authors:  B BENACERRAF; Z OVARY; K J BLOCH; E C FRANKLIN
Journal:  J Exp Med       Date:  1963-06-01       Impact factor: 14.307

View more
  20 in total

1.  The C-terminal sequences of the heavy chains of human immunoglobulin G myeloma proteins of differing isotopes and allotypes.

Authors:  J W Prahl
Journal:  Biochem J       Date:  1967-12       Impact factor: 3.857

2.  Behaviour of two IgG subclasses in transport of immunoglobulin across the human placenta.

Authors:  L C Mongan; C D Ockleford
Journal:  J Anat       Date:  1996-02       Impact factor: 2.610

3.  Identification of a gene locus for gamma-G-1 immunoglobulin H chains and its linkage to the H chain chromosome region in the mouse.

Authors:  J D Minna; G M Iverson; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1967-07       Impact factor: 11.205

Review 4.  Immunoglobulins.

Authors:  J Bradley
Journal:  J Med Genet       Date:  1974-03       Impact factor: 6.318

5.  The molecular defect in a protein (CRA) found in gamma-1 heavy chain disease, and its genetic implications.

Authors:  E C Franklin; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  1971-01       Impact factor: 11.205

6.  Variable regions of heavy and light polypeptide chains of the same gammaG-immunoglobulin molecule.

Authors:  P D Gottlieb; B A Cunningham; M J Waxdal; W H Konigsberg; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1968-09       Impact factor: 11.205

7.  Disulphide bridges of the heavy chain of human immunoglobulin G2.

Authors:  C Milstein; B Frangione
Journal:  Biochem J       Date:  1971-01       Impact factor: 3.857

8.  Human immunoglobulin subclasses. Partial amino acid sequence of the constant region of a gamma 4 chain.

Authors:  J R Pink; S H Buttery; G M De Vries; C Milstein
Journal:  Biochem J       Date:  1970-03       Impact factor: 3.857

9.  Antigenic heterogeneity among monoclonal IgM: observations on guinea-pig sera.

Authors:  F A Wollheim; G L Hansson
Journal:  Experientia       Date:  1975-10-15

10.  Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses. I. Catabolism of gammaG-myeloma proteins in man.

Authors:  H L Spiegelberg; B G Fishkin; H M Grey
Journal:  J Clin Invest       Date:  1968-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.